CLINICAL USE

Treatment of bleeding oesophageal varices

DOSE IN NORMAL RENAL FUNCTION

2 mg stat dose followed by 1–2 mg every 4–6 hours when required (until bleeding is controlled) for up to 72 hours

PHARMACOKINETICS

  • Molecular weight                           : 1227.4 (1437.6 as acetate)
  • %Protein binding                           : ≈30
  • %Excreted unchanged in urine     : <2
  • Volume of distribution (L/kg)       : 0.6–0.9
  • half-life – normal/ESRD (hrs)      : 50–70 minutes

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function. Use with caution
  • <10           : Dose as in normal renal function. Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                : Unknown dialysability. Dose as in GFR <10 mL/min
  • HD                     : Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux   : Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD      : Unknown dialysability. Dose as in GFR <10 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    With solvent provided

    Route

    IV

    Rate of Administration

    Comments

    Store reconstituted solution in the fridge and discard after 12 hours

    OTHER INFORMATION

    Maximum plasma levels are reached after 1–2 hours with a duration of action of 4–6 hours Initial response within 25–40 minutes, duration 2–10 hours Some studies have found it can be used to improve renal function in hepatorenal syndrome, in doses of about 3 mg per day for about 11 days May cause hypertension There is a case report of rhabdomyolysis .

  • Related News